portadores de acromegalia, proveniente de uma das regiões menos Tempo de diagnostico: data do início do tratamento, descrita em. cartarse acromegalia secundaria a la secreción ectópica de GH o de GHRH (« growth hormone releasing hormone») originada por otros tumores endocrinos. Meaning of acromegalia in the Spanish dictionary with examples of use. Synonyms for ACROMEGALIA. La palabra acromegalia procede del griego ἄκρος ‘extremo’ y μέγας, μεγάλη ‘grande’. .. acromegalia diagnostico. 8. acromegalia.
|Published (Last):||4 July 2010|
|PDF File Size:||19.99 Mb|
|ePub File Size:||18.40 Mb|
|Price:||Free* [*Free Regsitration Required]|
Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil.
Boguszewski V ; Marcello D. Jallad VI ; Nina R. Acromegaly is a disease fisioaptologia with increased morbidity and reduced life expectancy.
However, an early diagnosis and an effective treatment reduce the morbidity and normalize the mortality rate.
In this publication, the goal of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism is to disclose which clinical set should arouse the suspicious of acromegaly and how to diagnose it. Furthermore, we discuss the most effective and safe approach to perform the treatment of acromegaly, emphasizing that it must be carried out in reference centers.
Therefore, based on data published in journals with recognized scientific level and authors’ experience, recommendations are presented for diagnosis and treatment of the disease. Acromegaly; recommendations; dr treatment.
A taxa de cura foi menor no grupo dos macroadenomas: O volume tumoral deve ser avaliado por meio de exame de imagem a cada meses durante o tratamento medicamentoso.
Esses autores mostraram que esse risco foi dose-dependente fidiopatologia tempo-dependente. O volume tumoral deve ser avaliado a cada meses durante o tratamento com AS.
Acromegaliz do receptor de GH: Arq Bras Endocrinol Metabol. Acromegaly secondary to growth hormone-releasing hormone secreted by an incidentally discovered pheochromocytoma. Systemic complications of acromegaly: Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging.
Features at diagnosis of patients with acromegaly did not change from to J Clin Endocrinol Metab. Factors influencing mortality in acromegaly. Arq Bras Endocrinol Metab.
Meaning of “acromegalia” in the Spanish dictionary
Acromegaly with apparently normal GH secretion: Normal values of serum IGF-1 in adults: Factors controlling blood concentration of somatomedin C. Criteria for cure of acromegaly: A consensus on criteria for cure of acromegaly.
Current concepts in the biochemical assessment of the patient with acromegaly. Limited utility of oral glucose tolerance test in biochemically-active acromegaly. Epub Oct 6. Guidelines for acromegaly management: The outcome of surgery in patients with acromegaly using current criteria of biochemical ‘cure’. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Significance of “abnormal” nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels.
Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. Cabergoline in the treatment of hyperprolactinemia: Cabergoline in the treatment of acromegaly: Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy.
Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. Cabergoline and the risk of valvular lesions in endocrine disease. Quantitative analysis of somatostatin receptor subtypes gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR arcomegalia in acromegaly. Long-acting somatostatin analog therapy of acromegaly: Murray RD, Melmed S.
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. Treatment of acromegaly with octreotide-LAR: Primary treatment of acromegaly with octreotide LAR: Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: Optimizing medical fisiopatoligia of acromegaly: Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide Cisiopatologia.
Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly. Somatostatin analogs in acromegaly. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Acromegaliia treatment of acromegalic patients resistant to somatostatin analogs with the GH receptor antagonist pegvisomant: Epub Jan Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. The role of pegvisomant in the treatment of acromegaly.
Expert Opin Fisioatologia Ther. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: Lipodystrophy in patients with acromegaly receiving pegvisomant.
IHMC Public Cmaps (3)
Reevaluation of conventional pituitary irradiation in the therapy of acromegaly. Growth hormone pulsatility in acromegaly following radiotherapy. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. Jackson IM, Noren G.
Role of gamma knife therapy in the management of pituitary tumors. Gamma-knife radiosurgery in acromegaly: All the contents of this journal, except fisioopatologia otherwise noted, is licensed under a Creative Commons Attribution License. Services on Demand Journal. How to cite this article.